Patent · US Active

Modulation of huntingtin expression

US10202603B2 · kind B2 · utility

2Cited by

11References

16Claims

0Family size

Assignee

Ionis Pharmaceuticals, Inc. · US

Inventors

Gene Hung · San Francisco, US
C. Frank Bennett · Carlsbad, US
Susan M. Freier · San Diego, US
Holly Kordasiewicz · San Diego, US
Lisa Stanek · Natick, US
Don W. Cleveland · Alameda, US
Seng H. Cheng · Wellesley, US
Lamya Shihabuddin · Watertown, US

Key dates

Filing date	May 16, 2017
Grant date	Feb 12, 2019
Priority date	—
Expiry date	May 16, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/346
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.